Clinical characteristics of programmed death-1 inhibitors for older patients with advanced pancreatic cancer

Table 2 Univariate and multivariate analyses of progression-free survival among patients with advanced pancreatic carcinoma

Clinical variable	n	PFS univariate			PFS multivariate
		Median (months)	95%CI	P value	HR	95%CI	P value
Age, < 75 years	70	4.2	2.75-5.65	0.190
Sex, male	60	4.9	2.69-7.11	0.079
ECOG PS				< 0.001	0.268	0.124-0.582	0.001
0-1	65	8.6	6.32-10.88
2	34	1.7	1.24-2.16
HBV infection				0.698
Positive	9	5.1	3.64-6.56
Negative	90	5.5	3.77-7.23
Primary tumor location				0.030	1.380	0.810-2.351	0.236
Pancreatic head	46	4.5	3.02-5.98
Body & tail	53	6.0	3.97-8.03
Number of prior systemic therapy lines				0.033	0.763	0.579-1.006	0.055
0	70	6.3	4.63-7.98
1	29	2.6	1.37-3.83
Baseline serum CA199 levels (U/mL)				< 0.001	0.798	0.458-1.393	0.428
< 173.55	43	8.5	5.63-11.37
≥ 173.55	56	3.3	2.27-4.33
SII				0.001	0.682	0.321-1.452	0.321
< 531.575	49	8.5	6.14-10.86
≥ 531.575	50	3.3	1.84-4.76
NLR				< 0.001	0.714	0.312-1.634	0.425
< 2.1	38	8.6	6.16-11.04
≥ 2.1	61	3.3	2.01-4.59
PLR				0.076
< 217.91	74	6.3	5.07-7.53
≥ 217.91	25	4.0	3.18-4.82
PNI				< 0.001	2.988	1.633-5.469	< 0.001
< 45.6	54	3.3	2.01-4.59
≥ 45.6	45	8.5	6.00-11.00
HDL (mmol/L)				0.016	1.027	0.744-1.417	0.874
< 1.135	55	3.9	2.49-5.31
≥ 1.135	44	7.1	3.83-10.38
LDL (mmol/L)				0.559
< 2.26	52	4.9	2.48-7.32
≥ 2.26	47	5.5	3.29-7.71
TC (mmol/L)				0.472
< 4.045	56	4.5	2.77-6.23
≥ 4.045	43	6.3	4.96-7.64
TG (mmol/L)				< 0.001	0.343	0.167--0.706	0.004
< 1.315	55	8.5	6.08-10.92
≥ 1.315	44	2.1	1.36-2.84
With radiotherapy				0.019	0.941	0.489-1.810	0.855
Yes	24	7.1	4.07-10.13
No	75	4.0	2.79-5.21
With chemotherapy				0.123
Yes	79	6.0	4.80-7.20
No	20	1.9	1.02-2.78

ECOG PS: Eastern Cooperative Oncology Group performance status; HBV: Hepatitis B virus; CA199: Carbohydrate antigen 199; SII: Systemic immune-inflammation; NLR: Neutrophil-to-lymphocyte ratio; PLR: Platelet-to-lymphocyte ratio; PNI: Prognostic nutritional index; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; TC: Total cholesterol; TG: Triglyceride; PFS: Progression-free survival.